secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001558370-22-004156
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma reports Q4 net loss $10.6M; cash $147.7M; no Phase 2 for McArdle
-----------------------------------------------------------------------------

- Net loss for Q4 2021 was $10.6M ($0.43 per share) vs $6.3M in Q4 2020; full year net loss $39.8M.
- Cash, cash equivalents and short-term investments at Dec 31, 2021: $147.7M, sufficient into 2024.
- STRIDE Phase 2b PMM study enrollment ongoing; data expected in 2023; LC-FAOD data in 2Q 2022.
- REN001 in McArdle disease: no drug-related SAEs; company will not pursue Phase 2 for McArdle.
- Appointed Ashley Hall as Chief Development Officer and Eric Dube to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000155837022004156/0001558370-22-004156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000155837022004156/rphm-20220323x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-004156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer